Formulation and in-vitro evaluation of 5-flourouracil nanoparticles incorporated in sucralfate suspension as drug delivery system

The object of the present work was formulation and in vitro evaluation of 5-Fluorouracil nanoparticles incorporated in sucralfate suspension as drug delivery system. Sucralfate acts as the cytoproytective agent and carry the antineoplastic drug loaded nanoparticles to the carcinoma site in the g .i.t which will protect and alleviate the carcinoma. 5-Fluorouracil nanoparticles were prepared by nanoprecipitation method sodium alginate using as cross linking agent. Nanoparticulates were characterized in terms of drug entrapment efficiency, particle size, in vitro drug release were analyzed. Sucraalfate Suspension was prepared and evaluated for physical stability characteristics. An increase in the concentration of polymer increase in the entrapment efficiency and average particle size. FTIR and DSC studies exhibited there is no interaction between drug and excipients. The TEM analysis showed the particle size is ranges from170±3.2 to 560±2.3 and with optimum zeta potential. From the above results the formulation FN12 was to be best formulation 85.33±1 of drug release at the end of 12hr. Sucralfate suspension were prepared in order to select the optimum concentration of suspending agent and based on the physical stability parameters such as sedimentation volume, pH, and viscosity of these formulations FS5, FS10, FS15, were selected for incorporation of FN12 nanoparticles formulation. The Incorporated nanopparticulate formulation (FNS12) showed that the value “n” was greater than 1 indicating that super case-II mechanism on drug release behavior. The drug release follows zero order with regression value near to ( 0.859 to 0.965 ) with diffusion type of mechanism. Incorporation of nanoparticulates in to Sucralfate Suspension was a useful tool to carry the antineoplastic drug to carcinoma site.FSN12 showed outstanding characteristics of optimum Zetapotential and longer drug delivery. It could be a promising carrier for the oral administration of 5-Fluorouracil.